2 ms·
The hepatitis C cures was massively profitable. Gilead paid $11B for Pharmasset’s portfolio and everyone said they were dumb. They then had sales of $10.4B in
by refurb 6y ago
The hepatitis C cures was massively profitable. Gilead paid $11B for Pharmasset’s portfolio and everyone said they were dumb.
They then had sales of $10.4B in the first year on the market. That’s one year and one drug (they’ve developed newer drugs and launched those too).